Online citations, reference lists, and bibliographies.
← Back to Search

Clinical Development Of The Anti-CTLA-4 Antibody Tremelimumab.

A. Ribas
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Tremelimumab (formerly CP-675,206) is a fully human IgG2 monoclonal antibody tested in patients with cancer, of whom the majority have had metastatic melanoma. Clinical trials using tremelimumab demonstrate that this antibody can induce durable tumor regressions (up to 8 years at this time) in 7% to 10% of patients with metastatic melanoma. These tumor responses are mediated by the intratumoral infiltration of cytotoxic T lymphocytes (CTLs) as demonstrated in patient-derived tumor biopsies. Grade 3 or 4 toxicities in the range of 20% to 25% are mainly inflammatory or autoimmune in nature, which are on-target effects after inhibiting CTLA-4-mediated self-tolerance. The lack of survival advantage in the early analysis of a phase III clinical trial comparing tremelimumab with standard chemotherapy for metastatic melanoma highlights the importance of gaining a better understanding of how this antibody modulates the human immune system and how to better select patients for this mode of therapy.
This paper references
Immune response in malignant ascites from a melanoma patient treated with anti-CTLA-4 mAb
H. Harlin (2004)
10.1016/S0065-2776(06)90008-X
Checkpoint blockade in cancer immunotherapy.
A. Korman (2006)
10.1172/JCI21583
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
D. Munn (2004)
10.1200/JCO.2006.24.18_SUPPL.2542
Ex vivo blood stimulation assay as a translational research tool in the development of the ticilimumab (CP-675,206).
R. Millham (2006)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1038/nri1457
Ido expression by dendritic cells: tolerance and tryptophan catabolism
A. Mellor (2004)
10.1158/1078-0432.CCR-07-4797
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
C. Ménard (2008)
10.1097/00002371-200409000-00004
Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy
A. Ribas (2004)
10.1038/ni846
CTLA-4–Ig regulates tryptophan catabolism in vivo
U. Grohmann (2002)
10.1158/1078-0432.CCR-09-2376
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
A. Ribas (2009)
10.2967/jnumed.109.070946
Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
A. Ribas (2010)
10.1200/JCO.2005.01.109
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
10.1200/JCO.2005.23.16_SUPPL.7524
Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma
A. Ribas (2005)
10.1634/THEONCOLOGIST.12-7-873
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
A. Ribas (2007)
10.1097/CJI.0b013e3181dcd260
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
S. Agarwala (2010)
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1084/JEM.166.5.1351
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
M. Brüggemann (1987)
10.1200/JCO.2010.28.15_SUPPL.2609
Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.
M. A. Marshall (2010)
10.1038/nri1349
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
L. Chen (2004)
10.1200/JCO.2008.26.15_SUPPL.LBA9011
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
D. C. Hanson (2004)
10.1186/1479-5876-6-22
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
B. Comin-Anduix (2008)
10.1111/j.0105-2896.2006.00364.x
Phospho‐proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single‐cell level
O. Perez (2006)
10.1172/JCI106279
Metabolic properties of IgG subclasses in man.
A. Morell (1970)
10.1038/ni1003
Modulation of tryptophan catabolism by regulatory T cells
F. Fallarino (2003)
10.1002/cncr.21854
Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma
J. Reuben (2006)
10.1146/ANNUREV.IMMUNOL.19.1.565
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.
C. A. Chambers (2001)
10.1158/1078-0432.CCR-08-0783
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
A. Ribas (2009)
10.1158/1078-0432.CCR-05-0136
Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays
B. Comin-Anduix (2006)
10.1182/BLOOD-2006-04-010637
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.
A. Hryniewicz (2006)
10.1158/1078-0432.CCR-09-1254
Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
A. Ribas (2009)
10.1073/PNAS.0403342101
Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease.
S. Paust (2004)
10.2967/jnumed.108.051342
PET Imaging of Cancer Immunotherapy
P. Tumeh (2008)
10.1200/JCO.2008.19.2435
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
L. Camacho (2009)
10.1371/journal.pone.0012711
Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
B. Comin-Anduix (2010)



This paper is referenced by
10.1158/1078-0432.CCR-11-0407
CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
R. Huang (2011)
10.1016/j.coi.2014.01.002
Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
J. Pérez-Gracia (2014)
10.1111/bcp.12164
Novel antibodies targeting immune regulatory checkpoints for cancer therapy
C. Lee (2013)
Investigating the role of PD-L1 pathway in human ovarian cancer
Jay Chatterjee (2014)
Toll-like receptor agonists for cancer therapy
E. Vacchelli (2013)
10.1016/j.it.2013.07.003
B7 family checkpoint regulators in immune regulation and disease.
S. Ceeraz (2013)
10.1007/s10388-015-0484-6
Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society
H. Makuuchi (2015)
10.1007/978-4-431-55327-4_17
Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression
S. Suzuki (2015)
10.1016/j.acthis.2011.12.010
The characteristic expression of B7-associated proteins in Langerhans cell sarcoma.
H. Li (2012)
10.1016/j.ejca.2013.07.001
Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
C. Robert (2013)
10.1016/j.molonc.2014.07.027
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
M. R. Girotti (2014)
10.1200/JCO.2013.49.8311
Frequency of non-cancer-related pain in patients with cancer.
L. Barbera (2013)
10.9790/3013-262018
Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints
K. S. Yogesh (2012)
Modulation of T regulatory activity for cancer therapy
C. Ralph (2011)
10.1517/14712598.2014.890586
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma
S. Tomei (2014)
10.2147/CPAA.S45884
Use of ipilimumab in the treatment of melanoma
U. Acharya (2013)
10.3390/ANTIB4030225
B Cell Epitope-Based Vaccination Therapy
Y. Kametani (2015)
Immunological biomarkers of outcome in thoracic cancers
T. Meniawy (2016)
10.1007/s12094-012-0804-4
Advances in cutaneous melanoma
E. Espinosa (2012)
10.1007/978-3-662-44946-2_6
Overcoming Cancer Tolerance with Immune Checkpoint Blockade
G. Clifton (2015)
10.1038/nature10673
Cancer immunotherapy comes of age
I. Mellman (2011)
Cancer Immunotherapy Comes of Age
M. Karsy (2013)
10.1007/978-3-319-93530-0_7
Immune Checkpoint Inhibitors in Sarcoma
S. D'Angelo (2019)
10.1007/s00262-011-1108-1
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer
Shao-bo Yang (2011)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1016/j.ejca.2015.08.012
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Z. Eroglu (2015)
10.1200/JCO.2011.38.0899
Cancer immunotherapy comes of age.
S. Topalian (2011)
Foundation review : The future of antibodies as cancer drugs
J. Reichert (2012)
10.1159/000478081
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
S. Hwang (2018)
10.2147/ITT.S61647
CD28 co-stimulation in T-cell homeostasis: a recent perspective
N. Beyersdorf (2015)
10.3390/cancers11030305
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
M. Porcu (2019)
10.1021/mp300504z
Retaining antibodies in tumors with a self-assembling injectable system.
Y. Wen (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar